Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moETRAVIRINE (etravirine) by Johnson & Johnson is non-nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients, older [see, hiv-1 infection in treatment-experienced patients 2 years of age and 1 more indications. First approved in 2025.
Drug data last refreshed 19h ago
Non-Nucleoside Reverse Transcriptase Inhibitors
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Worked on ETRAVIRINE at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)
A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants
Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo